Experienced in Familial Hypertriglyceridemia

Hanqing Cai

Changchun, CN 
Experienced in Familial Hypertriglyceridemia
Changchun, CN 
OverviewLocationsClinical Research

Overview

Hanqing Cai practices in Changchun, China. Cai is rated as an Experienced expert by MediFind in the treatment of Familial Hypertriglyceridemia. Their top areas of expertise are Type 2 Diabetes (T2D), Werner Syndrome, Osteoporosis, and Familial Hypertriglyceridemia.

Their clinical research consists of co-authoring 18 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Familial Hypertriglyceridemia.

Locations

Changchun, 130022, China
Other Locations
Jilin, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)
Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3

18 Total Publications

Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study.
Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study.
Journal: EClinicalMedicine
Published: March 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Cai's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile